latest update:
[TrialBase DB]

trial summary · NCT07845825

Aprepitant for the Treatment of CLIFAHDD

Channeling Hope Trial 1: A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) of Chronic Aprepitant Use in Individuals With Congenital Contractures of the Limbs and Face, Hypotonia, and Development Delay (CLIFAHDD)

Trial record from the TrialBase DB dataset, status RECRUITING, condition CLIFAHDD, sponsored by The University of Texas Health Science Center at San Antonio. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07845825phase EARLY_PHASE1enrollment 5start 2026-10-31

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

There are no drug treatments for individuals with Congenital Contractures of the Limb and Face, Hypotonia, and Developmental Delay (CLIFAHDD), an ultra-rare and severe neurodevelopmental disease. The investigators have learned more about the cause of the disease and researched possible treatments based on both the cause of the disease and the way certain drugs work. The investigators are interested in understanding the safety of using aprepitant (a drug already approved by the United States Food \& Drug Administration \[FDA\] to treat nausea and vomiting for kids and adults who are receiving chemotherapy) on people diagnosed with CLIFAHDD. The overall goal of this Phase 1 study is to study whether this drug is safe for daily use in individuals with CLIFAHDD and to find more information on how it impacts daily functioning and quality of life. The total study will take around 8 months total. This includes the 90 days before the drug starts and the 21 days after the drug ends.

Source record: https://clinicaltrials.gov/study/NCT07845825

Facts

registry idNCT07845825
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phaseEARLY_PHASE1
study typeINTERVENTIONAL
lead conditionCLIFAHDD
sponsorThe University of Texas Health Science Center at San Antonio
sponsor classOTHER
enrollment5
start date2026-10-31
primary completion2027-05-31
completion2027-07-31
results postednot reported

Conditions

  • CLIFAHDD
  • Congenital Contractures of the Limbs and Face, Hypotonia, and Developmental Delay
  • NALCN Channelopathy
  • Ataxia - Other
  • Neurodevelopmental Disorder (Diagnosis)

Interventions

  • Aprepitant Powder for Oral Suspension

Countries

  • United States

Intervention types: DRUG

Work with this record